Results 11 to 20 of about 8,366 (155)

KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]

PLoS ONE
BackgroundGlobal surveillance indicates rising ceftazidime-avibactam resistance among carbapenem-resistant Klebsiella pneumoniae (CRKP), with sequence type 11 predominating in China. The contribution of blaKPC variants and porin alterations to high-level
Shulong Zhao, Lin Ye, Shuang Song, Jingfang Sun, Jinfeng Xu, Fei Jiang, Haiquan Kang   +6 more
doaj   +2 more sources

In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review [PDF]

New Microbes and New Infections
Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients.
Abolfazl Rafati Zomorodi, Leila Ghanbari_Afra, Hossein Faridafshar, Seyed Nooreddin Faraji, Fatemeh Zarepour, Maryamosadat Mavaei, Mohammad Rahmanian   +6 more
doaj   +2 more sources

Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.

PLoS ONE, 2021
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures.
Fangzhou Wang, Qian Zhou, Xiuwen Yang, Yan Bai, Junchang Cui   +4 more
doaj   +1 more source

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To report the in vitro susceptibility of Enterobacterales (n = 3905) and Pseudomonas aeruginosa (n = 1,109) isolates, collected from patients in sub-Saharan Africa (four countries) in 2017–2021, to a panel of 10 antimicrobial agents with a
Mark G. Wise, James A. Karlowsky, Meredith A. Hackel, Mohamed Amine Harti, Bontle M.E. Ntshole, Eva Njeri Njagua, Rita Oladele, Catherine Samuel, Shameema Khan, Jeannette Wadula, Warren Lowman, Busisani W. Lembede, Daniel F. Sahm   +12 more
doaj   +1 more source

Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria

Антибиотики и Химиотерапия, 2021
The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj   +1 more source

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

Antibiotics, 2021
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
George L. Daikos, Clóvis Arns da Cunha, Gian Maria Rossolini, Gregory G. Stone, Nathalie Baillon-Plot, Margaret Tawadrous, Paurus Irani   +6 more
doaj   +1 more source

Ceftazidime-avibactam

Revista Española de Quimioterapia, 2022
The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire   +2 more sources

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Antimicrobial Resistance and Infection Control, 2020
Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.
Hui Zhang, Yingchun Xu, Peiyao Jia, Ying Zhu, Ge Zhang, Jingjia Zhang, Simeng Duan, Wei Kang, Tong Wang, Ran Jing, Jingwei Cheng, Yali Liu, Qiwen Yang   +12 more
doaj   +1 more source

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

WIREs Mechanisms of Disease, 2022
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Luying Xiong, Xueting Wang, Yuan Wang, Wei Yu, Yanzi Zhou, Xiaohui Chi, Tingting Xiao, Yonghong Xiao   +7 more
openaire   +2 more sources